We are live on ! Find out more
MAM

MPM Asset Management Portfolio holdings

AUM $44.5M
1-Year Est. Return 47.28%
This Fund
S&P 500
This Quarter Est. Return
+46.94%
1 Year Est. Return
-47.28%
3 Year Est. Return
+5.89%
5 Year Est. Return
-18.52%
10 Year Est. Return
+3.53%
AUM
$598M
AUM Growth
+$129M
Cap. Flow
-$39.1M
Cap. Flow %
-6.55%
Top 10 Hldgs %
99.58%
Holding
16
New
1
Increased
–
Reduced
2
Closed
1

Top Buys

Rank Stock Value
1
CLCD
CoLucid Pharmaceuticals, Inc.
CLCD
+$187K

Top Sells

Rank Stock Value
1
NVRO
NEVRO CORP.
NVRO
+$16.8M
2
EIGR
Eiger BioPharmaceuticals, Inc.
EIGR
+$15.2M
3
EPZM
Epizyme, Inc
EPZM
+$7.37M

Sector Composition

Rank Sector Weight
1 Healthcare 98.41%
2 Miscellaneous 1.59%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RDUS
1
DELISTED
Radius Health, Inc.
RDUS
$395M 66.06%
5,831,253
– –
PTLA
2
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$55.6M 9.3%
1,220,672
– –
EPZM
3
DELISTED
Epizyme, Inc
EPZM
$42.7M 7.15%
1,781,086
-382,733
-18% -$7.37M
PETX
4
DELISTED
Aratana Therapeutics, Inc.
PETX
$32M 5.36%
2,118,845
– –
NVRO
5
DELISTED
NEVRO CORP.
NVRO
$19.2M 3.21%
356,704
-330,000
-48% -$16.8M
TARA icon
6
Protara Therapeutics
TARA
$226M
$17.6M 2.94%
24,585
– –
ALT icon
7
Altimmune
ALT
$605M
$11.4M 1.91%
21,159
– –
TRIV
8
DELISTED
TRIVASCULAR TECHONOLOGIES, INC, COMMON STOCK
TRIV
$9.51M 1.59%
1,776,692
– –
VSTM icon
9
Verastem
VSTM
$654M
$6.16M 1.03%
68,057
– –
HSTO
10
DELISTED
Histogen Inc. Common Stock
HSTO
$6.14M 1.03%
5,960
– –
SVRA icon
11
Savara
SVRA
$1.08B
$1.25M 0.21%
36,455
– –
ETRM
12
DELISTED
EnteroMedics Inc.
ETRM
$690K 0.12%
1,060
– –
SGMO
13
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$249K 0.04%
22,487
– –
CLCD
14
DELISTED
CoLucid Pharmaceuticals, Inc.
CLCD
$194K 0.03%
+21,806
New +$187K
MGNX icon
15
MacroGenics
MGNX
$263M
$120K 0.02%
3,168
– –
EIGR
16
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
– –
-1,779
Closed -$15.2M

Similar funds

WCPI
Wynnchurch Capital Partners IV Rosemont, Illinois $44.8M AUM 11.91% 1-Year Est. Return
BAM
Broadcrest Asset Management Winter Park, Florida $44.1M AUM 4.51% 1-Year Est. Return
WAMC
Western Asset Management Company Pasadena, California $45.2M AUM 6.96% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
CIEP
Constellation Investimentos e Participacoes Sao Paulo, Brazil $46.7M AUM 23.3% 1-Year Est. Return
IPI
Inflection Point Investments London, United Kingdom $46.9M AUM 18.35% 1-Year Est. Return
CC
Corton Capital Carrying Place, Ontario, Canada $40.7M AUM 52.32% 1-Year Est. Return
VSAM
Value Star Asset Management Hong Kong $49.2M AUM 60.1% 1-Year Est. Return

MPM Asset Management's Q2 2015 Portfolio in Review

As of Q2 2015, MPM Asset Management held 16 positions worth $598M, up 27% from $469M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

MPM Asset Management withdrew a net $39.1M in Q2 2015, closing 1 position and reducing 2 holdings. Its most notable exit was Eiger BioPharmaceuticals, Inc., an estimated $15.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 96% a quarter earlier, followed by Miscellaneous.

Against the trend, MPM Asset Management opened a new position in CoLucid Pharmaceuticals, Inc. worth $194K.

  • MPM Asset Management's largest Q2 2015 buy was CoLucid Pharmaceuticals, Inc.: 21,806 shares worth $194K.
  • MPM Asset Management's biggest Q2 2015 reduction was NEVRO CORP., cutting an estimated $16.8M.
  • MPM Asset Management fully exited Eiger BioPharmaceuticals, Inc. in Q2 2015, selling an estimated $15.2M.
  • MPM Asset Management's ten largest holdings make up 100% of its $598M portfolio in Q2 2015.
  • MPM Asset Management opened 1 new position and closed 1 in Q2 2015.
  • MPM Asset Management's portfolio value rose 27% quarter-over-quarter to $598M.

Based on MPM Asset Management's 13F filing for Q2 2015, filed 29 Jul 2015.